Regulation of glucose metabolism and the skeleton

Clinical Endocrinology

Volumn 75, Issue 2, 2011, Pages 147-155

  Ng, Kong Wah ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BETA 2 ADRENERGIC RECEPTOR; GLUCOSE; INSULIN; INSULIN RECEPTOR; LEPTIN; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN TYROSINE PHOSPHATASE;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL MODEL; ARTICLE; BONE METABOLISM; BONE REMODELING; BONE TISSUE; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS; ENERGY EXPENDITURE; ENERGY METABOLISM; ESP GENE; GENE; GENE DELETION; GENE EXPRESSION; GENETIC MODEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYPOINSULINEMIA; HYPOTHALAMUS; IN VITRO STUDY; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; LIPOLYSIS; METABOLIC REGULATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PANCREAS; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOGENE; SIGNAL TRANSDUCTION; SYSTEMIC CIRCULATION;

ANIMALS; BONE REMODELING; ENERGY METABOLISM; GLUCOSE; HUMANS; INSULIN; OSTEOBLASTS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1;

EID: 79960155579     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04133.x     Document Type: Article

References (79)

1. Strange, K., (2003) From genes to integrative physiology: ion channel and transporter biology in Caenorhabditis elegans. Physiological Reviews, 83, 377-415. (Pubitemid 36378676)
2. Kershaw, E.E., &, Flier, J.S., (2004) Adipose tissue as an endocrine organ. Journal of Clinical Endocrinology and Metabolism, 89, 2548-2556. (Pubitemid 38766330)
3. Pittas, A.G., Joseph, N.A., &, Greenberg, A.S., (2004) Adipocytokines and insulin resistance. Journal of Clinical Endocrinology and Metabolism, 89, 447-452. (Pubitemid 38269842)
4. Ducy, P., Amling, M., Takeda, S., et al. (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell, 100, 197-207. (Pubitemid 30064908)
5. Elefteriou, F., Ahn, J.D., Takeda, S., et al. (2005) Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature, 434, 514-520. (Pubitemid 40477060)
6. Elefteriou, F., Takeda, S., Ebihara, K., et al. (2004) Serum leptin level is a regulator of bone mass. Proceedings of the National Academy of Sciences of the United States of America, 101, 3258-3263. (Pubitemid 38327768)
7. Shi, Y., Yadav, V.K., Suda, N., et al. (2008) Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo. Proceedings of the National Academy of Sciences of the United States of America, 105, 20529-20533.
8. Singh, M.K., Elefteriou, F., &, Karsenty, G., (2008) Cocaine and amphetamine-regulated transcript may regulate bone remodeling as a circulating molecule. Endocrinology, 149, 3933-3941.
9. Karsenty, G., (2006) Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metabolism, 4, 341-348. (Pubitemid 44645074)
10. Cornish, J., Callon, K.E., Bava, U., et al. (2002) Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. Journal of Endocrinology, 175, 405-415. (Pubitemid 35414387)
11. Holloway, W.R., Collier, F.M., Aitken, C.J., et al. (2002) Leptin inhibits osteoclast generation. Journal of Bone and Mineral Research, 17, 200-209. (Pubitemid 34087652)
12. Pasco, J.A., Henry, M.J., Sanders, K.M., et al. (2004) Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. Journal of Bone and Mineral Research, 19, 19-24. (Pubitemid 41295133)
13. Schlienger, R.G., Kraenzlin, M.E., Jick, S.S., et al. (2004) Use of beta-blockers and risk of fractures. JAMA, 292, 1326-1332.
14. Reid, I.R., Gamble, G.D., Grey, A.B., et al. (2005) beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. Journal of Bone and Mineral Research, 20, 613-618. (Pubitemid 40393069)
15. Lee, N.K., Sowa, H., Hinoi, E., et al. (2007) Endocrine regulation of energy metabolism by the skeleton. Cell, 130, 456-469. (Pubitemid 47208519)
16. Mauro, L.J., Olmsted, E.A., Skrobacz, B.M., et al. (1994) Identification of a hormonally regulated protein tyrosine phosphatase associated with bone and testicular differentiation. The Journal of Biological Chemistry, 269, 30659-30667. (Pubitemid 24376554)
17. Dacquin, R., Mee, P.J., Kawaguchi, J., et al. (2004) Knock-in of nuclear localised beta-galactosidase reveals that the tyrosine phosphatase Ptprv is specifically expressed in cells of the bone collar. Developmental Dynamics, 229, 826-834. (Pubitemid 38429111)
18. Hinoi, E., Gao, N., Jung, D.Y., et al. (2008) The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. Journal of Cell Biology, 183, 1235-1242.
19. Hood, D.A., (2009) Mechanisms of exercise-induced mitochondrial biogenesis in skeletal muscle. Applied Physiology, Nutrition, and Metabolism, 34, 465-472.
20. Kadowaki, T., &, Yamauchi, T., (2005) Adiponectin and adiponectin receptors. Endocrine Reviews, 26, 439-451. (Pubitemid 40686653)
21. Hauschka, P.V., Lian, J.B., Cole, D.E., et al. (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiological Reviews, 69, 990-1047. (Pubitemid 19184853)
22. Price, P.A., (1989) Gla-containing proteins of bone. Connective Tissue Research, 21, 51-57; discussion 57-60.
23. Ducy, P., Desbois, C., Boyce, B., et al. (1996) Increased bone formation in osteocalcin-deficient mice. Nature, 382, 448-452. (Pubitemid 26264860)
24. Ferron, M., Hinoi, E., Karsenty, G., et al. (2008) Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proceedings of the National Academy of Sciences of the United States of America, 105, 5266-5270. (Pubitemid 351738545)
25. Kim, Y.S., Paik, I.Y., Rhie, Y.J., et al. (2010) Integrative physiology: defined novel metabolic roles of osteocalcin. Journal of Korean Medical Science, 25, 985-991.
26. Kream, B.E., Smith, M.D., Canalis, E., et al. (1985) Characterization of the effect of insulin on collagen synthesis in fetal rat bone. Endocrinology, 116, 296-302. (Pubitemid 15190482)
27. Pun, K.K., Lau, P., &, Ho, P.W., (1989) The characterization, regulation, and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line. Journal of Bone and Mineral Research, 4, 853-862. (Pubitemid 20065695)
28. Ituarte, E.A., Halstead, L.R., Iida-Klein, A., et al. (1989) Glucose transport system in UMR-106-01 osteoblastic osteosarcoma cells: regulation by insulin. Calcified Tissue International, 45, 27-33. (Pubitemid 19166468)
29. Gandhi, A., Beam, H.A., O'Connor, J.P., et al. (2005) The effects of local insulin delivery on diabetic fracture healing. Bone, 37, 482-490. (Pubitemid 41317321)
30. Botolin, S., &, McCabe, L.R., (2007) Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology, 148, 198-205. (Pubitemid 46021451)
31. Martin, L.M., &, McCabe, L.R., (2007) Type I diabetic bone phenotype is location but not gender dependent. Histochemistry and Cell Biology, 128, 125-133. (Pubitemid 47197932)
32. Ferron, M., Wei, J., Yoshizawa, T., et al. (2010) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell, 142, 296-308.
33. Schlessinger, J., (2000) Cell signaling by receptor tyrosine kinases. Cell, 103, 211-225.
34. Kenner, K.A., Anyanwu, E., Olefsky, J.M., et al. (1996) Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling. The Journal of Biological Chemistry, 271, 19810-19816.
35. Delibegovic, M., Zimmer, D., Kauffman, C., et al. (2009) Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes, 58, 590-599.
36. Fulzele, K., Riddle, R.C., DiGirolamo, D.J., et al. (2010) Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell, 142, 309-319.
37. Bialek, P., Kern, B., Yang, X., et al. (2004) A twist code determines the onset of osteoblast differentiation. Developmental Cell, 6, 423-435. (Pubitemid 38364573)
38. Rached, M.T., Kode, A., Silva, B.C., et al. (2010) FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. Journal of Clinical Investigation, 120, 357-368.
39. Nakae, J., Biggs III, W.H., Kitamura, T., et al. (2002) Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nature Genetics, 32, 245-253.
40. Engelke, J.A., Hale, J.E., Suttie, J.W., et al. (1991) Vitamin K-dependent carboxylase: utilization of decarboxylated bone Gla protein and matrix Gla protein as substrates. Biochimica et Biophysica Acta, 1078, 31-34.
41. Schaller, S., Henriksen, K., Sorensen, M.G., et al. (2005) The role of chloride channels in osteoclasts: ClC-7 as a target for osteoporosis treatment. Drug News & Perspectives, 18, 489-495. (Pubitemid 43094116)
42. Lee, N.K., &, Karsenty, G., (2008) Reciprocal regulation of bone and energy metabolism. Trends in Endocrinology and Metabolism, 19, 161-166. (Pubitemid 351847838)
43. Zhang, M., Xuan, S., Bouxsein, M.L., et al. (2002) Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. The Journal of Biological Chemistry, 277, 44005-44012. (Pubitemid 36157826)
44. Hinoi, E., Gao, N., Jung, D.Y., et al. (2009) An Osteoblast-dependent mechanism contributes to the leptin regulation of insulin secretion. Annals of the New York Academy of Sciences, 1173 (Suppl 1), E20-30.
45. Cousin, W., Courseaux, A., Ladoux, A., et al. (2004) Cloning of hOST-PTP: the only example of a protein-tyrosine-phosphatase the function of which has been lost between rodent and human. Biochemical and Biophysical Research Communications, 321, 259-265. (Pubitemid 39055633)
46. Kindblom, J.M., Ohlsson, C., Ljunggren, O., et al. (2009) Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. Journal of Bone and Mineral Research, 24, 785-791.
47. Yeap, B.B., Chubb, S.A., Flicker, L., et al. (2010) Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. European Journal of Endocrinology, 163, 265-272.
48. Saleem, U., Mosley Jr, T.H., &, Kullo, I.J., (2010) Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 1474-1478.
49. Im, J.A., Yu, B.P., Jeon, J.Y., et al. (2008) Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clinica Chimica Acta, 396, 66-69.
50. Pittas, A.G., Harris, S.S., Eliades, M., et al. (2009) Association between serum osteocalcin and markers of metabolic phenotype. Journal of Clinical Endocrinology and Metabolism, 94, 827-832.
51. Zhou, M., Ma, X., Li, H., et al. (2009) Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. European Journal of Endocrinology, 161, 723-729.
52. Yeap, B.B., Chubb, S.A., Flicker, L., et al. (2011) Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The health in men study. Osteoporosis International, Feb 26 [Epub ahead of publication].
53. Kanazawa, I., Yamaguchi, T., Yamamoto, M., et al. (2009) Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism, 94, 45-49.
54. Kanazawa, I., Yamaguchi, T., Yamauchi, M., et al. (2010) Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporosis International, 22, 187-194.
55. Yoshida, M., Booth, S.L., Meigs, J.B., et al. (2008) Phylloquinone intake, insulin sensitivity, and glycemic status in men and women. American Journal of Clinical Nutrition, 88, 210-215. (Pubitemid 351988701)
56. Hwang, Y.C., Jeong, I.K., Ahn, K.J., et al. (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metabolism Research and Reviews, 25, 768-772.
57. Shea, M.K., Gundberg, C.M., Meigs, J.B., et al. (2009) Gamma-carboxylation of osteocalcin and insulin resistance in older men and women. American Journal of Clinical Nutrition, 90, 1230-1235.
58. Motyl, K.J., McCabe, L.R., &, Schwartz, A.V., (2010) Bone and glucose metabolism: a two-way street. Archives of Biochemistry and Biophysics, 503, 2-10.
59. Nimptsch, K., Hailer, S., Rohrmann, S., et al. (2007) Determinants and correlates of serum undercarboxylated osteocalcin. Annals of Nutrition and Metabolism, 51, 563-570. (Pubitemid 351315923)
60. Kawai, M., &, Rosen, C.J., (2010) PPARgamma: a circadian transcription factor in adipogenesis and osteogenesis. Nature Reviews. Endocrinology, 6, 629-636.
61. Kemink, S.A., Hermus, A.R., Swinkels, L.M., et al. (2000) Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. Journal of Endocrinological Investigation, 23, 295-303. (Pubitemid 30426548)
62. Janghorbani, M., Feskanich, D., Willett, W.C., et al. (2006) Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes Care, 29, 1573-1578. (Pubitemid 44127583)
63. Petit, M.A., Paudel, M.L., Taylor, B.C., et al. (2010) Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. Journal of Bone and Mineral Research, 25, 285-291.
64. Vashishth, D., (2005) Collagen glycation and its role in fracture properties of bone. Journal of Musculoskeletal and Neuronal Interactions, 5, 316.
65. Kahn, S.E., Haffner, S.M., Heise, M.A., et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine, 355, 2427-2443. (Pubitemid 44903747)
66. Loke, Y.K., Singh, S., &, Furberg, C.D., (2009) Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ, 180, 32-39.
67. Habib, Z.A., Havstad, S.L., Wells, K., et al. (2010) Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism, 95, 592-600.
68. Sharma, A.M., &, Staels, B., (2007) Review: peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. Journal of Clinical Endocrinology and Metabolism, 92, 386-395.
69. Lecka-Czernik, B., Gubrij, I., Moerman, E.J., et al. (1999) Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. Journal of Cellular Biochemistry, 74, 357-371. (Pubitemid 29344887)
70. Shockley, K.R., Lazarenko, O.P., Czernik, P.J., et al. (2009) PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. Journal of Cellular Biochemistry, 106, 232-246.
71. Kubota, N., Terauchi, Y., Miki, H., et al. (1999) PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Molecular Cell, 4, 597-609. (Pubitemid 29531139)
72. Akune, T., Ohba, S., Kamekura, S., et al. (2004) PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. Journal of Clinical Investigation, 113, 846-855. (Pubitemid 38544143)
73. Grey, A., Bolland, M., Gamble, G., et al. (2007) The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. Journal of Clinical Endocrinology and Metabolism, 92, 1305-1310. (Pubitemid 46556402)
74. Lecka-Czernik, B., Ackert-Bicknell, C., Adamo, M.L., et al. (2007) Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology, 148, 903-911. (Pubitemid 46143190)
75. Shinoda, Y., Yamaguchi, M., Ogata, N., et al. (2006) Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. Journal of Cellular Biochemistry, 99, 196-208. (Pubitemid 44297964)
76. Williams, G.A., Wang, Y., Callon, K.E., et al. (2009) In vitro and in vivo effects of adiponectin on bone. Endocrinology, 150, 3603-3610.
77. Johnell, O., Scheele, W.H., Lu, Y., et al. (2002) Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. Journal of Clinical Endocrinology and Metabolism 87, 985-992. (Pubitemid 36121052)
78. Fukumoto, S., &, Martin, T.J., (2009) Bone as an endocrine organ. Trends in Endocrinology and Metabolism, 20, 230-236.
79. Oury, F., Sumara, G., Sumara, O., et al. (2010) Endocrine regulation of male fertility by the skeleton. Cell, 144, 796-809.